TAMMY ULEBERG: Open Payments
NPI 1710051628 · MINOT, ND. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$439 in 20 payments from 9 companies in 2025. Trend: 2023 $248 · 2024 $347 · 2025 $439
Food & beverage: $439
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $110 |
| Axsome Therapeutics, Inc. | 4 | $105 |
| Alkermes, Inc. | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Neurocrine BioSciences, Inc. | 2 | $33 |
| E.R. Squibb & Sons, L.L.C. | 1 | $30 |
| Collegium Pharmaceutical, Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
Products named: CAPLYTA, Auvelity, ARISTADA, REXULTI, INGREZZA, COBENFY, Jornay PM, AUSTEDO XR.
Industry payments across ND — which companies pay providers there.
